Skip to main content


Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea

  • Jungsil Ro1Email author,
  • Sohee Park1,
  • Sung- Bae Kim2,
  • Tae You Kim3,
  • Young Hyuk Im4,
  • Sun Young Rha5,
  • Joo Seop Chung6,
  • Hanlim Moon7 and
  • Sergio Santillana7
BMC Cancer201212:322

DOI: 10.1186/1471-2407-12-322

Received: 8 March 2012

Accepted: 26 June 2012

Published: 28 July 2012

Back to article

Open Peer Review reports

Pre-publication versions of this article and author comments to reviewers are available by contacting

Original Submission
8 Mar 2012 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
20 Apr 2012 Reviewed Reviewer Report - Etienne BRAIN
1 Jun 2012 Reviewed Reviewer Report - Masakazu Toi
20 Jun 2012 Author responded Author comments - Jungsil Ro
Resubmission - Version 3
20 Jun 2012 Submitted Manuscript version 3
26 Jun 2012 Editorially accepted
28 Jul 2012 Article published 10.1186/1471-2407-12-322

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article and author comments to reviewers are available by contacting All previous versions of the manuscript and all author responses to the reviewers are also available.

You can find further information about the peer review system here.

Authors’ Affiliations

National Cancer Center Hospital and Research Institute
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine
Department of Internal Medicine, Seoul National University Hospital
Department of Hematology-Oncology, Samsung Medical Center
Department of Internal Medicine, Severance Hospital
Deparment of Medical Oncology, Pusan National University Hospital
Department of Medical (AP Oncology), GlaxoSmithKline Oncology